Literature DB >> 1645733

Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro.

S Shuman1.   

Abstract

Purified vaccinia virus DNA topoisomerase I forms a cleavable complex with duplex DNA at a conserved sequence element 5'(C/T)CCTTdecreases in the incised DNA strand. DNase I footprint studies show that vaccinia topoisomerase protects the region around the site of covalent adduct formation from nuclease digestion. On the cleaved DNA strand, the protected region extends from +13 to -13 (+1 being the site of cleavage). On the noncleaved strand, the protected region extends from +13 to -9. Similar nuclease protection is observed for a mutant topoisomerase (containing a Tyr ---- Phe substitution at the active site amino acid 274) that is catalytically inert and does not form the covalent intermediate. Thus, vaccinia topoisomerase is a specific DNA binding protein independent of its competence in transesterification. By studying the cleavage of a series of 12-mer DNA duplexes in which the position of the CCCTTdecreases motif within the substrate is systematically phased, the "minimal" substrate for cleavage has been defined; cleavage requires six nucleotides upstream of the cleavage site and two nucleotides downstream of the site. An analysis of the cleavage of oligomer substrates mutated singly in the CCCTT sequence reveals a hierarchy of mutational effects based on position within the pentamer motif and the nature of the sequence alteration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645733

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3' mononucleotide overhang.

Authors:  C Cheng; S Shuman
Journal:  Nucleic Acids Res       Date:  2000-05-01       Impact factor: 16.971

2.  Genome-scale cloning and expression of individual open reading frames using topoisomerase I-mediated ligation.

Authors:  J A Heyman; J Cornthwaite; L Foncerrada; J R Gilmore; E Gontang; K J Hartman; C L Hernandez; R Hood; H M Hull; W Y Lee; R Marcil; E J Marsh; K M Mudd; M J Patino; T J Purcell; J J Rowland; M L Sindici; J P Hoeffler
Journal:  Genome Res       Date:  1999-04       Impact factor: 9.043

3.  Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks.

Authors:  C Cheng; S Shuman
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

4.  Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding.

Authors:  J Sekiguchi; S Shuman
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

5.  Semi-artificial Fluorescent Molecular Machine for DNA Damage Detection.

Authors:  Vladimir V Didenko; Candace L Minchew; Stewart Shuman; David S Baskin
Journal:  Nano Lett       Date:  2004-12       Impact factor: 11.189

6.  Chemical and traditional mutagenesis of vaccinia DNA topoisomerase provides insights to cleavage site recognition and transesterification chemistry.

Authors:  Lyudmila Yakovleva; Shengxi Chen; Sidney M Hecht; Stewart Shuman
Journal:  J Biol Chem       Date:  2008-03-25       Impact factor: 5.157

7.  Mechanism and specificity of DNA strand exchange catalyzed by vaccinia DNA topoisomerase type I.

Authors:  Mary R Stahley; James T Stivers
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

8.  Intramolecular synapsis of duplex DNA by vaccinia topoisomerase.

Authors:  S Shuman; D G Bear; J Sekiguchi
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

9.  DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate.

Authors:  B O Petersen; S Shuman
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

10.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.